Skip to Content

Xigduo XR Approval History

  • FDA approved: Yes (First approved October 30th, 2014)
  • Brand name: Xigduo XR
  • Generic name: dapagliflozin and metformin hydrochloride
  • Dosage form: Extended-Release Tablets
  • Company: AstraZeneca
  • Treatment for: Diabetes, Type 2

Xigduo XR (dapagliflozin and metformin hydrochloride) is a once-daily sodium-glucose cotransporter 2 (SGLT2) inhibitor and biguanide combination for the treatment of type 2 diabetes.

Development History and FDA Approval Process for Xigduo XR

Oct 30, 2014Approval FDA Approves Xigduo XR (dapagliflozin and metformin hydrochloride) for Type 2 Diabetes

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.